Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

BI Partners with Sinopharm for Promotion of Sifrol and Pradaxa in China

Fineline Cube Nov 21, 2024

German pharmaceutical major Boehringer Ingelheim (BI) has entered into a partnership with China-based Sinopharm Group...

Company Medical Device

Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection

Fineline Cube Nov 21, 2024

US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...

Company Deals

CStone Pharmaceuticals Partners with Pharmalink for Suemalimab Commercialization in MENA and South Africa

Fineline Cube Nov 21, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced a strategic commercial collaboration with Pharmalink Store –...

Company Drug

NMPA Approves Alpha Biopharma’s Zorifertinib for First-Line NSCLC Treatment with CNS Metastases

Fineline Cube Nov 21, 2024

The National Medical Products Administration (NMPA) has granted approval to China-based Alpha Biopharma’s zorifertinib, commercially...

Company Drug

Pfizer’s Hympavzi Receives European Commission Approval for Hemophilia A and B

Fineline Cube Nov 21, 2024

US pharmaceutical major Pfizer Inc. (NYSE: PFE) has announced that the European Commission (EC) has...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study

Fineline Cube Nov 21, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...

Company Deals

Shenzhen Chipscreen Biosciences Announces Private Placement to Fund Drug R&D and Expansion

Fineline Cube Nov 21, 2024

China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced plans for a...

Company Drug

US FDA Grants ODD to Ractigen’s siRNA Therapy RAG-21 for ALS Treatment

Fineline Cube Nov 21, 2024

China-based small activating RNA (saRNA) drug developer, Ractigen Therapeutics, has announced that it has received...

Company Drug

UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa

Fineline Cube Nov 21, 2024

Belgium-based biopharmaceutical company UCB (FRA: UNC) has announced that the US Food and Drug Administration...

Company Deals

Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies

Fineline Cube Nov 21, 2024

US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...

Legal / IP

BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa

Fineline Cube Nov 21, 2024

China-based BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), which is in the process of...

Company Deals

Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102

Fineline Cube Nov 20, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...

Company Drug

GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus

Fineline Cube Nov 20, 2024

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has announced positive headline results from the Phase...

Company Drug

Astellas Pharma’s Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter

Fineline Cube Nov 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4568) has announced that its supplemental New Drug Application (sNDA)...

Company Deals

Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan

Fineline Cube Nov 20, 2024

Germany-based Bayer AG (ETR: BAYN) has announced a significant collaboration and license agreement with US-based...

Company Drug

MSD Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial

Fineline Cube Nov 20, 2024

US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has released positive topline results from...

Company Deals

Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student

Fineline Cube Nov 20, 2024

French pharmaceutical company Servier and the US-based Dana-Farber Cancer Institute have announced the start of...

Company Medical Device

New Horizon Health Registers Three Medical Devices in Hong Kong’s Department of Health

Fineline Cube Nov 20, 2024

Hangzhou-based New Horizon Health Ltd (HKG: 6606) has announced the successful registration of three of...

Policy / Regulatory

NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections

Fineline Cube Nov 20, 2024

The National Medical Products Administration (NMPA) has taken a significant step towards enhancing transparency in...

Company Drug

Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV

Fineline Cube Nov 20, 2024

China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...

Posts pagination

1 … 285 286 287 … 688

Recent updates

  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
  • AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
  • Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
  • Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Company Medical Device

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.